...
首页> 外文期刊>Pakistan journal of medical sciences. >Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with nonproliferative diabetic retinopathy
【24h】

Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with nonproliferative diabetic retinopathy

机译:尼帕非那克预防非增生性糖尿病视网膜病变患者白内障手术后黄斑水肿的效果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To determine the efficacy of topical Nepafenac (0.1%), administered post-operatively in prevention of Macular Edema (ME), after cataract surgery in patients with Non-Proliferative Diabetic Retinopathy (NPDR).Methods: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from Sep 2015 to Sep 2016. Sixty eyes of 60 patients with NPDR underwent phacoemulsification with intraocular lens implantation. Group 1 received 0.1% Nepafenac, 8-hourly, in operated eye after cataract surgery for three months, along with routine post-operative medications. Group-2 received only routine post-operative medications. ME was defined as increase in Central Macular Thickness (CMT) of >10% from pre-operative baseline, measured using spectral domain optical coherence tomography.Results: Mean age of study population was 60.97±4.91 years. Out of 60 patients, 34 (56.7%) were males and 24 (43.3%) were females. Mean pre-operative CMT, 3 months post-operative CMT, mean change in CMT and mean frequency change in CMT of Group-1 was 226.5±10.86μm, 228.83±14.56 μm, 2.33±10.45 μm and 1.05% respectively. Mean pre-operative CMT, three months post-operative CMT, mean change in CMT and mean frequency change in CMT in Group-2 was 223.93±11.69μm, 236.17±16.16 μm, 12.23±12.40μm and 5.51% respectively. ME was observed in one patient (3.3%) in Group-1, and seven patients (23.3%) in Group 2. The difference of mean change in CMT and frequency change in CMT between groups was statistically significant (p<0.05).Conclusion: 0.1% topical Nepafenac is effective in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR).
机译:目的:确定非扩散性糖尿病性视网膜病(NPDR)患者白内障手术后局部应用尼泊芬那(0.1%)预防黄斑水肿(ME)的疗效。方法:进行了这项随机对照试验于2015年9月至2016年9月在拉瓦尔品第的武装部队眼科研究所(AFIO)进行。60眼NPDR患者的60眼接受了人工晶状体植入术的超声乳化术。第一组,在白内障手术后三个月内,每8小时接受0.1%的Nepafenac,并接受常规的术后药物治疗。第2组仅接受常规的术后药物治疗。 ME被定义为使用光谱域光学相干断层扫描测量的距术前基线的中央黄斑厚度(CMT)增加> 10%。结果:研究人群的平均年龄为60.97±4.91岁。在60例患者中,男性34例(56.7%),女性24例(43.3%)。第一组的平均术前CMT,术后3个月CMT,CMT平均变化和CMT平均频率变化分别为226.5±10.86μm,228.83±14.56μm,2.33±10.45μm和1.05%。第二组的平均术前CMT,术后三个月的CMT,CMT的平均变化和CMT的平均频率变化分别为223.93±11.69μm,236.17±16.16μm,12.23±12.40μm和5.51%。第1组中有1例(3.3%)观察到ME,第2组中有7例(23.3%)观察到ME。两组之间CMT的平均变化和CMT的频率变化的差异具有统计学意义(p <0.05)。 :0.1%的奈帕芬酸局部用药可有效预防非增生性糖尿病性视网膜病(NPDR)患者白内障手术后的黄斑水肿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号